Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Jimmey Kimmel returns
  • IND vs BAN LIVE
  • Typhoon Ragasa
  • H-1B visa
  • India-EU trade deal
  • Rapture Tok
  • Zubeen Garg death
fp-logo
Medical stent regulation row: Govt's move to prohibit companies from withdrawing stents is wrong
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit

Medical stent regulation row: Govt's move to prohibit companies from withdrawing stents is wrong

Nivedita Saksena • April 27, 2017, 16:20:01 IST
Whatsapp Facebook Twitter

Over the last few months, the National Pharmaceutical Pricing Authority (NPPA) has been in a tussle with manufacturers of cardiac stents.

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
Medical stent regulation row: Govt's move to prohibit companies from withdrawing stents is wrong

Over the last few months, the National Pharmaceutical Pricing Authority (NPPA) has been in a tussle with manufacturers of cardiac stents. The issue of contention has been the high prices charged by manufacturers (or retailers) for these stents, making them unaffordable for a majority of patients in the country. According to the report of a committee examining issues relating to the essentiality of coronary stents, 41.38 percent of the total expenditure on Percutaneous Coronary Interventions (PCI) is paid for by patients out of their own pockets.

STORY CONTINUES BELOW THIS AD

Therefore, it becomes essential to take steps to ensure that these devices are accessible and affordable. The method that the government has chosen to adopt for this purpose is to cap the prices of these devices.

More from India
Curfew imposed in Leh after statehood protests turn violent; LG cites conspiracy, vows strict action Curfew imposed in Leh after statehood protests turn violent; LG cites conspiracy, vows strict action How soon could ‘Day Zero droughts’ become a reality? How soon could ‘Day Zero droughts’ become a reality?

Attempts by cardiac stent manufacturers Abbott and Medtronic to remove their ‘high end’ stents from the market have been thwarted by the government by making use of mechanisms provided for under the Drug Pricing Control Order, 2013 (DPCO, 2013).

However, a reading of the orders suggests that the manner in which these powers have been exercised may be legally suspect. It is important that the government addresses this issue if it wants to ensure that the benefits of these measures accrue to the patients as intended.

The story so far 

Price caps on cardiac stents were first placed following an order of the Supreme Court in Birender Sangwan versus Union of India, directing the government to examine the feasibility of including cardiac stents under the National List of Essential Medicines (NLEM), A two-member committee appointed by the government agreed, and further recommended that the prices be set by the pricing authority NPPA. The NPPA, after assessing production costs and price margins, fixed the cost of cardiac stents at Rs 7260 for Bare Metal Stents and Rs 29,600 for Drug Eluting Stents.

Impact Shorts

More Shorts
Police arrest Mohammad Yousuf, who helped terrorists in Pahalgam attack, in J&K: Sources

Police arrest Mohammad Yousuf, who helped terrorists in Pahalgam attack, in J&K: Sources

Indian-American diaspora's silence on US policy is surprising: Tharoor

Indian-American diaspora's silence on US policy is surprising: Tharoor

Companies are pulling out stents from the markets after NPPA regulation.
Companies are pulling out stents from the markets after NPPA regulation.

Fearing that some stent manufacturers would cease the production of stents, it also invoked paragraph three of the DPCO, 2013, directing companies to maintain an uninterrupted supply of all its coronary stents for six months from the date of the order. In cases of emergency, urgency or non-commercial use in public interest, paragraph 3 allows the government to direct manufacturers to increase or continue the production of a notified medical device and to sell these to institutions, hospitals or any agency.

STORY CONTINUES BELOW THIS AD

In response, cardiac stent manufacturers Abbott, Medtronic and Boston Scientific Corporation filed requests under paragraph 21(2) of the DPCO, 2013, to allow them to withdraw certain categories of their stents from the market. On 26th April, the NPPA issued office memorandums rejecting the requests by Abbott and Medtronic on two grounds.

First, it stated that the application was not made in the format prescribed in the DPCO, 2013. Second, it stated that once an order has been made under paragraph 3 to continue the production of a device, companies cannot approach the NPPA under paragraph 21(2) requesting to withdraw their stents from the market. While the intention behind these orders may be laudable, the reasons provided may not be legally sound.

On the first ground, a simple procedural irregularity arising out of an omitted signature cannot be grounds to pass an adverse order. The companies must be allowed to rectify the errors and make a fresh application. On the second ground, more importantly, the NPPA claims that paragraph three overrides paragraph 21(2). However, such an interpretation is not borne out by a reading of the DPCO, 2013 itself. As the DPCO is structured, paragraph 3 and paragraph 21(2) operate independent of each other. There is nothing to suggest that once an order has been made to continue the production of stents, companies are excluded from making an application to withdraw these stents from the market.

STORY CONTINUES BELOW THIS AD

Given the high stakes (and amount of money) involved, it seems unlikely that the stent manufacturers will let this remain unchallenged. At the very least, we may see these issues being litigated and these orders may be challenged in court.

What the government can do

If these stent manufacturers do go to court, there is a chance that the judges do not agree with the interpretation in these orders and they are struck down. However, there is a way in which the government can ensure that the companies do not stop manufacturing these stents, while also staying in the bounds of the law. To do this, it should consider making use of a mechanism provided for under paragraph 21(2) itself, which states that once a request for withdrawal of stents from the market has been received, the Government may, in public interest, direct them to continue with the required level of production for a period of one year.

STORY CONTINUES BELOW THIS AD

However, the provision does not specify a limit on the number of times such an order may be renewed. Therefore, theoretically, the government could keep this order in place for as long as necessary and justified in the public interest.

The Supreme Court has on numerous occasions upheld price control as a valid means to ensure access to drugs and has directed the government to ensure that essential drugs do not fall out of price control. While the economic merit of these measures may be debated, it would be difficult to argue that any of them have been illegal.

Since they may prove to be unpopular, it is necessary that the government only takes measures that are consistent with the DPCO.

It is now up to the government to determine whether they have been effective in improving the health of patients, and to ensure that continued access to medical devices that may save their lives.

STORY CONTINUES BELOW THIS AD
Tags
Supreme Court InMyOpinion Abbott NPPA DPCO Medtronic Percutaneous Coronary Interventions
  • Home
  • India
  • Medical stent regulation row: Govt's move to prohibit companies from withdrawing stents is wrong
End of Article
Latest News
Find us on YouTube
Subscribe
  • Home
  • India
  • Medical stent regulation row: Govt's move to prohibit companies from withdrawing stents is wrong
End of Article

Impact Shorts

Police arrest Mohammad Yousuf, who helped terrorists in Pahalgam attack, in J&K: Sources

Police arrest Mohammad Yousuf, who helped terrorists in Pahalgam attack, in J&K: Sources

Jammu and Kashmir Police arrested Mohammad Yousuf Kataria, allegedly a Lashkar-e-Taiba and The Resistance Front member, for providing logistical support in the Pahalgam attack that killed 26 people. He was identified through weapons analysis in 'Operation Mahadev'.

More Impact Shorts

Top Stories

Zelenskyy warns world of ‘most destructive arms race in history,’ says weapons will decide who survives

Zelenskyy warns world of ‘most destructive arms race in history,’ says weapons will decide who survives

US opposes Russia’s bid for UN aviation seat, says Moscow makes airspace ‘more dangerous’

US opposes Russia’s bid for UN aviation seat, says Moscow makes airspace ‘more dangerous’

Israel’s Netanyahu vows combined military-diplomatic push to free Gaza hostages

Israel’s Netanyahu vows combined military-diplomatic push to free Gaza hostages

Trump administration to redirect $1.8 billion in foreign aid to ‘America First’ priorities

Trump administration to redirect $1.8 billion in foreign aid to ‘America First’ priorities

Zelenskyy warns world of ‘most destructive arms race in history,’ says weapons will decide who survives

Zelenskyy warns world of ‘most destructive arms race in history,’ says weapons will decide who survives

US opposes Russia’s bid for UN aviation seat, says Moscow makes airspace ‘more dangerous’

US opposes Russia’s bid for UN aviation seat, says Moscow makes airspace ‘more dangerous’

Israel’s Netanyahu vows combined military-diplomatic push to free Gaza hostages

Israel’s Netanyahu vows combined military-diplomatic push to free Gaza hostages

Trump administration to redirect $1.8 billion in foreign aid to ‘America First’ priorities

Trump administration to redirect $1.8 billion in foreign aid to ‘America First’ priorities

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Enjoying the news?

Get the latest stories delivered straight to your inbox.

Subscribe

QUICK LINKS

  • Mumbai Rains
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV